Back to School: How biopharma can reboot drug development. Access exclusive analysis here

BioMarin, Merck KGaA, Daiichi Sankyo deal

BMRN reacquired Canadian rights to tetrahydrobiopterin ( BH4), including Kuvan sapropterin, from MRK's Merck

Read the full 142 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE